PT1644340E - Compostos de n-[({4¿-piperazina substituída-1-sulfonilmetil)alquil}]-n-hidroxiformamida como inibidores de metaloproteinases - Google Patents

Compostos de n-[({4¿-piperazina substituída-1-sulfonilmetil)alquil}]-n-hidroxiformamida como inibidores de metaloproteinases Download PDF

Info

Publication number
PT1644340E
PT1644340E PT04743053T PT04743053T PT1644340E PT 1644340 E PT1644340 E PT 1644340E PT 04743053 T PT04743053 T PT 04743053T PT 04743053 T PT04743053 T PT 04743053T PT 1644340 E PT1644340 E PT 1644340E
Authority
PT
Portugal
Prior art keywords
sulfonylmethyl
alkyl
metalloproteinase inhibitors
substituted piperazine
hydroxyformamide
Prior art date
Application number
PT04743053T
Other languages
English (en)
Portuguese (pt)
Inventor
Maurice R V Finlay
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1644340(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1644340E publication Critical patent/PT1644340E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT04743053T 2003-06-27 2004-06-23 Compostos de n-[({4¿-piperazina substituída-1-sulfonilmetil)alquil}]-n-hidroxiformamida como inibidores de metaloproteinases PT1644340E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (1)

Publication Number Publication Date
PT1644340E true PT1644340E (pt) 2009-01-02

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04743053T PT1644340E (pt) 2003-06-27 2004-06-23 Compostos de n-[({4¿-piperazina substituída-1-sulfonilmetil)alquil}]-n-hidroxiformamida como inibidores de metaloproteinases

Country Status (33)

Country Link
US (1) US7485644B2 (https=)
EP (1) EP1644340B1 (https=)
JP (1) JP4701167B2 (https=)
KR (1) KR20060026440A (https=)
CN (2) CN102229589A (https=)
AR (1) AR044931A1 (https=)
AT (1) ATE414063T1 (https=)
AU (1) AU2004251104B2 (https=)
BR (1) BRPI0411929A (https=)
CA (1) CA2529468A1 (https=)
CO (1) CO5650254A2 (https=)
CY (1) CY1108757T1 (https=)
DE (1) DE602004017733D1 (https=)
DK (1) DK1644340T3 (https=)
ES (1) ES2315675T3 (https=)
HR (1) HRP20090009T3 (https=)
IL (1) IL172615A0 (https=)
IS (1) IS8257A (https=)
MX (1) MXPA05013460A (https=)
MY (1) MY138680A (https=)
NO (1) NO20060444L (https=)
NZ (1) NZ544208A (https=)
PL (1) PL1644340T3 (https=)
PT (1) PT1644340E (https=)
RU (1) RU2351595C2 (https=)
SA (1) SA04250224B1 (https=)
SE (1) SE0301922D0 (https=)
SI (1) SI1644340T1 (https=)
TW (1) TW200524898A (https=)
UA (1) UA81491C2 (https=)
UY (1) UY28387A1 (https=)
WO (1) WO2005000822A1 (https=)
ZA (1) ZA200510458B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
ZA200803327B (en) * 2005-10-26 2009-09-30 Serono Lab Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
DK2597084T3 (en) * 2010-07-08 2016-08-15 Kaken Pharma Co Ltd N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
EP1187811B1 (en) * 1999-06-04 2007-03-07 AstraZeneca AB Inhibitors of metalloproteinases
PL365909A1 (en) * 2000-02-21 2005-01-10 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
MXPA04010555A (es) * 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
ATE411303T1 (de) * 2003-06-19 2008-10-15 Ucb Pharma Sa Hydroxamatsulfonamide als inhibitoren von cd23- shedding

Also Published As

Publication number Publication date
JP2007516164A (ja) 2007-06-21
JP4701167B2 (ja) 2011-06-15
ZA200510458B (en) 2007-03-28
TW200524898A (en) 2005-08-01
CY1108757T1 (el) 2014-04-09
MXPA05013460A (es) 2006-03-09
CN102229589A (zh) 2011-11-02
ES2315675T3 (es) 2009-04-01
CA2529468A1 (en) 2005-01-06
CN1812974A (zh) 2006-08-02
US7485644B2 (en) 2009-02-03
UY28387A1 (es) 2005-01-31
HK1086835A1 (en) 2006-09-29
NO20060444L (no) 2006-03-22
SE0301922D0 (sv) 2003-06-27
US20070197542A1 (en) 2007-08-23
RU2351595C2 (ru) 2009-04-10
SI1644340T1 (sl) 2009-02-28
RU2005141058A (ru) 2006-07-27
EP1644340A1 (en) 2006-04-12
UA81491C2 (en) 2008-01-10
CN1812974B (zh) 2011-06-29
WO2005000822A1 (en) 2005-01-06
IS8257A (is) 2006-01-23
MY138680A (en) 2009-07-31
KR20060026440A (ko) 2006-03-23
EP1644340B1 (en) 2008-11-12
DE602004017733D1 (de) 2008-12-24
BRPI0411929A (pt) 2006-08-15
PL1644340T3 (pl) 2009-04-30
ATE414063T1 (de) 2008-11-15
CO5650254A2 (es) 2006-06-30
IL172615A0 (en) 2006-04-10
AU2004251104A1 (en) 2005-01-06
AR044931A1 (es) 2005-10-12
AU2004251104B2 (en) 2008-05-08
DK1644340T3 (da) 2009-02-02
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
HRP20090009T3 (en) 2009-02-28

Similar Documents

Publication Publication Date Title
AP1967A (en) Thiazolidinone compounds as inhibitors of Hyak3
IL190372A0 (en) Biaryl substituted heterocycle inhibitors of lta4h
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
PL372198A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
PL1635840T3 (pl) Tiofenopirymidynony jako inhibitory dehydrogenazy 17-beta-hydroksysteroidowej
SI1611112T1 (sl) Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov
PL378405A1 (pl) Pochodne malonoamidu jako inhibitory <$Egamma> - sekretazy
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
NO20042080L (no) Inhibitorer for post-prolin spaltningsproteaser
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
SE0502338L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
EP1624844A4 (en) FORMULATION BASED ON MORINDA CITRIFOLIA FOR THE INHIBITION OF METASTASES OF CARCINOGENIC CELLS
ZA200604551B (en) Biaryl sulfonamides as MMP inhibitors
PT1663958E (pt) Compostos contendo haloalquilo como inibidores de protease de cisteína
PL379385A1 (pl) Nowe związki 2-pirydynyloetylobenzamidowe
IL158770A0 (en) N-formyl hydroxylamine compounds as inhibitors of pdf
IL175106A0 (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
DE602004011221D1 (de) 3-amino-pyrrolidine als inhibitoren der monoamin-wiederaufnahme
IL150806A0 (en) Piperidine-and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
PT1644340E (pt) Compostos de n-[({4¿-piperazina substituída-1-sulfonilmetil)alquil}]-n-hidroxiformamida como inibidores de metaloproteinases
ZA200603153B (en) Pyridine compounds as inhibitors of dipetidyl peptidase IV
WO2004099124A3 (de) Neue bioisostere von actinonin
PL375304A1 (en) N-sulfonylpiperidines as metalloproteinase inhibitors (tace)
EP1551794A4 (en) UREIDO-SUBSTITUTED ANILINE COMPOUNDS SUITABLE AS SERINPROTEASE INHIBITORS
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa